Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of Roxadustat on the Pharmacokinetics of Simvastatin, Rosuvastatin, and Atorvastatin in Healthy Subjects: Results From 3 Phase 1, Open-Label, 1-Sequence, Crossover Studies.
Groenendaal-van de Meent D, den Adel M, Kerbusch V, van Dijk J, Shibata T, Kato K, Schaddelee M. Groenendaal-van de Meent D, et al. Among authors: schaddelee m. Clin Pharmacol Drug Dev. 2022 Apr;11(4):486-501. doi: 10.1002/cpdd.1076. Epub 2022 Feb 19. Clin Pharmacol Drug Dev. 2022. PMID: 35182045 Free PMC article. Clinical Trial.
The Hypoxia-inducible Factor Prolyl-Hydroxylase Inhibitor Roxadustat (FG-4592) and Warfarin in Healthy Volunteers: A Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction Study.
Groenendaal-van de Meent D, den Adel M, Rijnders S, Krebs-Brown A, Kerbusch V, Golor G, Schaddelee M. Groenendaal-van de Meent D, et al. Among authors: schaddelee m. Clin Ther. 2016 Apr;38(4):918-28. doi: 10.1016/j.clinthera.2016.02.010. Epub 2016 Mar 4. Clin Ther. 2016. PMID: 26947173 Clinical Trial.
Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor.
Groenendaal-van de Meent D, Adel MD, Noukens J, Rijnders S, Krebs-Brown A, Mateva L, Alexiev A, Schaddelee M. Groenendaal-van de Meent D, et al. Among authors: schaddelee m. Clin Drug Investig. 2016 Sep;36(9):743-751. doi: 10.1007/s40261-016-0422-y. Clin Drug Investig. 2016. PMID: 27352308 Free PMC article.
Effect of Multiple Doses of Omeprazole on the Pharmacokinetics, Safety, and Tolerability of Roxadustat in Healthy Subjects.
Groenendaal-van de Meent D, den Adel M, van Dijk J, Barroso-Fernandez B, El Galta R, Golor G, Schaddelee M. Groenendaal-van de Meent D, et al. Among authors: schaddelee m. Eur J Drug Metab Pharmacokinet. 2018 Dec;43(6):685-692. doi: 10.1007/s13318-018-0480-z. Eur J Drug Metab Pharmacokinet. 2018. PMID: 29752643 Free PMC article. Clinical Trial.
Effect of the Phosphate Binders Sevelamer Carbonate and Calcium Acetate on the Pharmacokinetics of Roxadustat After Concomitant or Time-separated Administration in Healthy Individuals.
Groenendaal-van de Meent D, Kerbusch V, Barroso-Fernandez B, den Adel M, van Dijk J, Golor G, Schaddelee M. Groenendaal-van de Meent D, et al. Among authors: schaddelee m. Clin Ther. 2021 Jun;43(6):1079-1091. doi: 10.1016/j.clinthera.2021.03.025. Epub 2021 May 5. Clin Ther. 2021. PMID: 33962762 Free article. Clinical Trial.
Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
Krauwinkel W, van Dijk J, Schaddelee M, Eltink C, Meijer J, Strabach G, van Marle S, Kerbusch V, van Gelderen M. Krauwinkel W, et al. Among authors: schaddelee m. Clin Ther. 2012 Oct;34(10):2144-60. doi: 10.1016/j.clinthera.2012.09.010. Clin Ther. 2012. PMID: 23063375 Clinical Trial.
Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron.
Dickinson J, Lewand M, Sawamoto T, Krauwinkel W, Schaddelee M, Keirns J, Kerbusch V, Moy S, Meijer J, Kowalski D, Morton R, Lasseter K, Riff D, Kupčová V, van Gelderen M. Dickinson J, et al. Among authors: schaddelee m. Clin Drug Investig. 2013 Jan;33(1):11-23. doi: 10.1007/s40261-012-0031-3. Clin Drug Investig. 2013. PMID: 23208320 Clinical Trial.
Single dose pharmacokinetics and absolute bioavailability of mirabegron, a β₃-adrenoceptor agonist for treatment of overactive bladder.
Eltink C, Lee J, Schaddelee M, Zhang W, Kerbusch V, Meijer J, van Marle S, Grunenberg N, Kowalski D, Drogendijk T, Moy S, Iitsuka H, van Gelderen M, Matsushima H, Sawamoto T. Eltink C, et al. Among authors: schaddelee m. Int J Clin Pharmacol Ther. 2012 Nov;50(11):838-50. doi: 10.5414/CP201782. Int J Clin Pharmacol Ther. 2012. PMID: 22943933 Clinical Trial.
The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol.
Krauwinkel W, Dickinson J, Schaddelee M, Meijer J, Tretter R, van de Wetering J, Strabach G, van Gelderen M. Krauwinkel W, et al. Among authors: schaddelee m. Eur J Drug Metab Pharmacokinet. 2014 Mar;39(1):43-52. doi: 10.1007/s13318-013-0133-1. Epub 2013 Jun 1. Eur J Drug Metab Pharmacokinet. 2014. PMID: 23728524 Clinical Trial.
A quantitative benefit-risk assessment approach to improve decision making in drug development: Application of a multicriteria decision analysis model in the development of combination therapy for overactive bladder.
de Greef-van der Sandt I, Newgreen D, Schaddelee M, Dorrepaal C, Martina R, Ridder A, van Maanen R. de Greef-van der Sandt I, et al. Among authors: schaddelee m. Clin Pharmacol Ther. 2016 Apr;99(4):442-51. doi: 10.1002/cpt.271. Epub 2015 Nov 13. Clin Pharmacol Ther. 2016. PMID: 26422298 Clinical Trial.
21 results